Dianthus Therapeutics, Inc. (NASDAQ:DNTH) Receives Average Rating of “Buy” from Analysts

Dianthus Therapeutics, Inc. (NASDAQ:DNTH) has been given an average recommendation of “Buy” by the ten research firms that are currently covering the stock, Marketbeat Ratings reports. Eight analysts have rated the stock with a buy recommendation and two have given a strong buy recommendation to the company. The average 12-month target price among analysts that have covered the stock in the last year is $44.71.

Several brokerages recently commented on DNTH. Baird R W upgraded shares of Dianthus Therapeutics to a “strong-buy” rating in a research note on Friday, July 26th. Cantor Fitzgerald started coverage on Dianthus Therapeutics in a report on Thursday, June 27th. They issued an “overweight” rating for the company. Wedbush dropped their price target on Dianthus Therapeutics from $38.00 to $36.00 and set an “outperform” rating on the stock in a research note on Friday, August 9th. HC Wainwright reiterated a “buy” rating and issued a $40.00 price objective on shares of Dianthus Therapeutics in a research note on Monday, August 12th. Finally, Lifesci Capital upgraded shares of Dianthus Therapeutics to a “strong-buy” rating in a research report on Tuesday, June 11th.

Institutional Investors Weigh In On Dianthus Therapeutics

Large investors have recently modified their holdings of the stock. SG Americas Securities LLC acquired a new position in Dianthus Therapeutics in the 2nd quarter valued at $112,000. The Manufacturers Life Insurance Company acquired a new position in shares of Dianthus Therapeutics during the second quarter worth about $236,000. WINTON GROUP Ltd purchased a new position in Dianthus Therapeutics during the second quarter worth about $265,000. Point72 DIFC Ltd acquired a new stake in Dianthus Therapeutics in the second quarter valued at about $334,000. Finally, Virtu Financial LLC purchased a new stake in Dianthus Therapeutics in the 1st quarter valued at approximately $390,000. Hedge funds and other institutional investors own 47.53% of the company’s stock.

Dianthus Therapeutics Stock Performance

DNTH opened at $28.00 on Wednesday. Dianthus Therapeutics has a one year low of $6.58 and a one year high of $33.77. The company has a market cap of $821.77 million, a P/E ratio of -4.80 and a beta of 1.85. The business’s 50-day simple moving average is $27.98 and its 200-day simple moving average is $26.16.

Dianthus Therapeutics (NASDAQ:DNTH) last announced its quarterly earnings results on Thursday, August 8th. The company reported ($0.51) EPS for the quarter, missing the consensus estimate of ($0.50) by ($0.01). The company had revenue of $1.86 million during the quarter, compared to analysts’ expectations of $0.63 million. Dianthus Therapeutics had a negative net margin of 1,376.42% and a negative return on equity of 21.03%. As a group, analysts predict that Dianthus Therapeutics will post -2.32 earnings per share for the current fiscal year.

Dianthus Therapeutics Company Profile

Dianthus Therapeutics, Inc, a clinical-stage biotechnology company, develops complement therapeutics for patients with severe autoimmune and inflammatory diseases. It is developing DNTH103, a monoclonal antibody, which is in Phase 2 clinical trial, for the treatment of generalized myasthenia gravis, multifocal motor neuropathy, and chronic inflammatory demyelinating polyneuropathy.